Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 10 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Febuxostat Tablets. These tablets are used to treat high uric acid levels in patients with gout who cannot use allopurinol. The drug will be manufactured at the company's facility in Ahmedabad, India. The press release also notes that Febuxostat tablets had significant annual sales in the United States according to market data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases